Compare Nutanix Inc (NTNX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs TG Therapeutics Inc — how do they compare? Nutanix Inc trades at $64.42 (market cap $17.48B), while TG Therapeutics Inc trades at $49.52 (market cap $7.58B). The key difference: Nutanix Inc is far larger — about 2.3× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| NTNX | TGTX | |
|---|---|---|
Market Cap | $17.48B | $7.58B |
Sector | Technology | Health |
52-Week High | $81.12 | $59.06 |
52-Week Low | $34.41 | $26.94 |
Enterprise Value | $16.99B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $64.65, up 0.29% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.47 versus $0.36, maintaining a streak of earnings surprises. Revenue growth accelerated to $2.7B in 2026 with net profit margin expanding to 10.03%, while institutional interest remains strong with recent acquisitions by Arrowstreet Capital and CalPERS.
Outlook remains positive with 62.5% analyst buy ratings and a $57.80 consensus target, though current price exceeds this level. Key risks include supply chain constraints affecting hardware lead times and competitive pressure in cloud infrastructure. The stock's elevated P/E of 67.71 requires continued execution to justify valuation, with Q2 2026 earnings on August 26th serving as near-term catalyst.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
